Andrew is Associate Professor of Cancer Immunology at the University of Nottingham and has over 25 years of experience in biomedical research. Andrew undertook his PhD at Edinburgh University in 1989 and has since lead research teams at ICRF/CRUK Leeds University (UK), Duke University (USA) and Nottingham University (UK) where he presently leads the Host-Tumour Interactions Group in the Division of Cancer and Stem Cells at the School of Medicine. He was involved in the development of anti-TNF strategies for treatment of Rheumatoid Arthritis in the 1980s and in the 1990s developed the background research for number of first-in-man clinical trials of novel DNA-vaccines for Melanoma and Breast Cancer.  His academic research interests focus on the immuno-biology of malignant melanoma of the skin and in particular intracellular signalling pathways in Dendritic Cells.  Andrew is a member of the Editorial Board of the Future Medicine journal Immunotherapy and has published more than 70 peer-reviewed research papers, review articles and book chapters.



Scientific Director: Andrew M. Jackson, PhD

Providing medical innovation through biological understanding and intelligent application.